Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

BACKGROUND: This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD). METHODS: Patients with moderate-to-severe IBD initiated on adalimumab therapy wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinzaki, Shinichiro, Matsuoka, Katsuyoshi, Tanaka, Hiroki, Takeshima, Fuminao, Kato, Shingo, Torisu, Takehiro, Ohta, Yuki, Watanabe, Kenji, Nakamura, Shiro, Yoshimura, Naoki, Kobayashi, Taku, Shiotani, Akiko, Hirai, Fumihito, Hiraoka, Sakiko, Watanabe, Mamoru, Matsuura, Minoru, Nishimoto, Shohei, Mizuno, Shinta, Iijima, Hideki, Takehara, Tetsuo, Naka, Tetsuji, Kanai, Takanori, Matsumoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article—Alimentary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137624/
https://www.ncbi.nlm.nih.gov/pubmed/33942166
http://dx.doi.org/10.1007/s00535-021-01793-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137624/
https://www.ncbi.nlm.nih.gov/pubmed/33942166
http://dx.doi.org/10.1007/s00535-021-01793-0

Ejemplares similares